Suven grants exclusive license to Taro Pharmaceuticals
07 March 2014 | News | By BioSpectrum Bureau
Suven grants exclusive license to Taro Pharmaceuticals
Malathion lotion is indicated for patients infected with Pediculus humanus capitis (head lice and their ova) of the scalp hair.
In this regard, Taro will pay Suven a royalty and the arrangement is effective until April 2028, unless otherwise terminated.
